Novo Nordisk A/S (NYSE:NVO) Receives Average Recommendation of “Hold” from Brokerages

Shares of Novo Nordisk A/S (NYSE:NVO) have received a consensus rating of “Hold” from the twenty-three research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, seventeen have issued a hold rating and five have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $65.5625.

NVO has been the topic of several analyst reports. Wolfe Research started coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Finally, Weiss Ratings downgraded shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in NVO. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $25,000. WealthCollab LLC lifted its holdings in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the last quarter. American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $28,000. Jackson Grant Investment Advisers Inc. acquired a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $29,000. Finally, Maseco LLP acquired a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $29,000. 11.54% of the stock is currently owned by institutional investors.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s Wegovy access continues to expand, and a recent U.K. approval has added to optimism around demand for its GLP-1 franchise, supporting the stock’s recent rebound. Article Title
• Positive Sentiment: The company launched Awiqli, the world’s first once-weekly basal insulin, in India, a move that could strengthen Novo Nordisk’s diabetes footprint in a large and fast-growing market. Article Title
• Positive Sentiment: Analysts and commentators continue to argue that the stock still has a long-term bull case, with some saying the decline from highs has made the valuation more attractive relative to the company’s growth prospects. Article Title
• Neutral Sentiment: Several articles note that investors are simply watching Novo Nordisk more closely, suggesting heightened interest rather than a single new fundamental catalyst. Article Title
• Neutral Sentiment: Coverage around a Wegovy label update and broader GLP-1 enthusiasm is keeping the name in focus, but the market appears to be balancing this against the risk that competition and earnings pressure could limit upside. Article Title
• Negative Sentiment: Recent commentary also highlights rising competition in the obesity and diabetes drug markets, which could pressure Novo Nordisk’s growth and margins over time. Article Title
• Negative Sentiment: One recent market note said NVO has been slipping relative to the broader market, reflecting some near-term profit taking after the stock’s strong run. Article Title

Novo Nordisk A/S Trading Up 1.2%

Shares of NYSE NVO traded up $0.61 during trading on Friday, hitting $49.49. 6,314,361 shares of the company traded hands, compared to its average volume of 10,696,942. The firm has a market capitalization of $220.96 billion, a P/E ratio of 11.62, a P/E/G ratio of 4.51 and a beta of 0.77. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $45.57 and a 200-day moving average price of $45.87. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The firm had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, equities analysts predict that Novo Nordisk A/S will post 3.38 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.